GLUD1 and non-small cell lung carcinoma: Glutamine addiction plays a crucial role in acquired drug resistance and metastasis of NSCLC and targeting the glutamate dehydrogenase 1 (GLUD1) pathway may provide a promising therapeutic strategy for NSCLC (8).